(Q38484840)

3 September 2017

1 reference

title

Small molecule inhibitor of apoptosis proteins antagonists: a patent review (English)

1 reference

3 September 2017

Alexander W Hird

1

1 reference

3 September 2017

Brian M Aquila

2

1 reference

3 September 2017

Edward J Hennessy

3

1 reference

3 September 2017

Melissa M Vasbinder

4

1 reference

3 September 2017

Bin Yang

5

1 reference

3 September 2017

language of work or name

English

0 references

publication date

18 May 2015

1 reference

Expert Opinion on Therapeutic Patents

3 September 2017

published in

1 reference

3 September 2017

volume

25

1 reference

3 September 2017

issue

7

1 reference

3 September 2017

page(s)

755-774

1 reference

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

21 January 2018

Apoptosis and disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

The role of apoptosis in the pathogenesis and treatment of diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

IAP proteins: blocking the road to death's door

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

IAP proteins as targets for drug development in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

XIAP: apoptotic brake and promising therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

The inhibitor of apoptosis proteins as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Structural and biochemical basis of apoptotic activation by Smac/DIABLO

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Structural basis of IAP recognition by Smac/DIABLO

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Development of Peptidomimetics Targeting IAPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Small-molecule SMAC mimetics as new cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Structural basis for bivalent Smac-mimetics recognition in the IAP protein family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Structural Insight into Inhibitor of Apoptosis Proteins Recognition by a Potent Divalent Smac-Mimetic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Smac mimetics and TNFalpha: a dangerous liaison?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-α pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Design, synthesis and evaluation of inhibitor of apoptosis protein (IAP) antagonists that are highly selective for the BIR2 domain of XIAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Targeting the inhibitor of Apoptosis Protein BIR3 binding domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Small-molecule pan-IAP antagonists: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

Recurrent hepatocellular carcinoma: it's the virus!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1041922

10.1517/13543776.2015.1041922

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference